STOCK TITAN

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to five new employees on July 31, 2024. These awards, made under the company's 2024 Inducement Stock Incentive Plan, include:

1. Stock options to purchase 91,200 shares of common stock at $7.00 per share, vesting over four years.

2. 37,300 restricted stock units (RSUs), vesting in equal annual installments over four years.

These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to serve as an inducement for new employees joining the company.

Verve Therapeutics, un'azienda in fase clinica che sviluppa medicinali genetici per le malattie cardiovascolari, ha annunciato il conferimento di premi azionari a cinque nuovi dipendenti il 31 luglio 2024. Questi premi, concessi nell'ambito del Piano di Incentivazione delle Azioni per il 2024 dell'azienda, includono:

1. Opzioni su azioni per l'acquisto di 91.200 azioni ordinarie a $7,00 per azione, con maturazione su un periodo di quattro anni.

2. 37.300 unità di azioni vincolate (RSU), che maturano in rate annuali uguali nel corso di quattro anni.

Questi concessioni sono in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) e sono progettate per fungere da incentivo per i nuovi dipendenti che entrano a far parte dell'azienda.

Verve Therapeutics, una empresa en fase clínica que desarrolla medicamentos genéticos para enfermedades cardiovasculares, ha anunciado la concesión de premios de acciones a cinco nuevos empleados el 31 de julio de 2024. Estos premios, otorgados bajo el Plan de Incentivo Accionario 2024 de la empresa, incluyen:

1. Opciones sobre acciones para comprar 91,200 acciones comunes a $7.00 por acción, que se asignarán durante un período de cuatro años.

2. 37,300 unidades de acciones restringidas (RSUs), que se asignarán en cuotas anuales iguales durante cuatro años.

Estas concesiones están de acuerdo con la Regla de Listado 5635(c)(4) de Nasdaq y están diseñadas para servir como un incentivo para los nuevos empleados que se unen a la empresa.

심혈관 질환을 위한 유전자 의약품을 개발하는 임상 단계의 기업인 Verve Therapeutics는 2024년 7월 31일에 다섯 명의 새로운 직원에게 주식 보상을 수여한다고 발표했습니다. 이러한 보상은 회사의 2024 유도 주식 인센티브 계획에 따라 제공되며, 내용은 다음과 같습니다:

1. 91,200주의 보통주를 주당 $7.00에 구매할 수 있는 주식 옵션, 4년 간 분할 지급됩니다.

2. 37,300개의 제한 주식 유닛(RSU)가 있으며, 이는 4년에 걸쳐 연간 균등 분할 지급됩니다.

이러한 제공은 Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어지며, 회사에 새로 합류하는 직원들을 위한 유도책으로 설계되었습니다.

Verve Therapeutics, une entreprise en phase clinique développant des médicaments génétiques pour les maladies cardiovasculaires, a annoncé l'octroi de récompenses en actions à cinq nouveaux employés le 31 juillet 2024. Ces récompenses, accordées dans le cadre du Plan d'Incitation aux Actions 2024 de l'entreprise, comprennent :

1. Options d'achat d'actions pour acquérir 91 200 actions ordinaires au prix de 7,00 $ l'action, avec un acquittement sur une période de quatre ans.

2. 37 300 unités d'actions restreintes (RSUs), acquises en versements annuels égaux sur quatre ans.

Ces attributions sont conformes à la règle de cotation Nasdaq 5635(c)(4) et sont conçues pour servir d'incitation aux nouveaux employés rejoignant l'entreprise.

Verve Therapeutics, ein Unternehmen in der klinischen Phase, das genetische Arzneimittel für Herz-Kreislauf-Erkrankungen entwickelt, hat die Gewährung von Aktienvergütungen an fünf neue Mitarbeiter am 31. Juli 2024 angekündigt. Diese Vergütungen, die im Rahmen des Aktienanreizplans 2024 des Unternehmens gewährt werden, umfassen:

1. Aktienoptionen zum Kauf von 91.200 Stammaktien zu einem Preis von 7,00 $ pro Aktie, die über einen Zeitraum von vier Jahren fällig werden.

2. 37.300 beschränkte Aktieneinheiten (RSUs), die in gleichen jährlichen Raten über vier Jahre fällig werden.

Diese Gewährungen entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und sind als Anreiz für neue Mitarbeiter gedacht, die dem Unternehmen beitreten.

Positive
  • Attraction of new talent with equity incentives
  • Alignment of employee interests with company performance through stock options and RSUs
Negative
  • Potential dilution of existing shareholders' equity

BOSTON, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on July 31, 2024, the company granted equity awards to five new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received stock options to purchase an aggregate of 91,200 shares of the company’s common stock and an aggregate of 37,300 restricted stock units (RSUs). The options have an exercise price of $7.00 per share, which is equal to the closing price of the company’s common stock on the date of grant. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to each such employee’s continued service with the company on each such vesting date. The RSUs will vest in equal annual installments on the first four anniversaries of October 1, 2024, subject to each such employee’s continued service with the company on each such vesting date.

About Verve Therapeutics 
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally-tolerated standard of care therapies. For more information, please visit www.VerveTx.com.

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com

Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com


FAQ

What equity awards did Verve Therapeutics (VERV) grant to new employees on July 31, 2024?

Verve Therapeutics granted stock options to purchase 91,200 shares of common stock at $7.00 per share and 37,300 restricted stock units (RSUs) to five new employees.

How do the stock options granted by Verve Therapeutics (VERV) on July 31, 2024 vest?

The stock options vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in equal monthly installments over the following three years.

What is the vesting schedule for the RSUs granted by Verve Therapeutics (VERV) on July 31, 2024?

The RSUs vest in equal annual installments on the first four anniversaries of October 1, 2024, subject to continued employment.

Under which plan did Verve Therapeutics (VERV) grant the equity awards announced on August 2, 2024?

The equity awards were granted under Verve Therapeutics' 2024 Inducement Stock Incentive Plan.

Verve Therapeutics, Inc.

NASDAQ:VERV

VERV Rankings

VERV Latest News

VERV Stock Data

399.85M
84.63M
7.75%
90.94%
19.2%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON